pharma news, views and analysis

in News
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535m
October 18, 2019 Share
X
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535m
https://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
in News
AZ/Daiichi’s possible breast cancer blockbuster gets fast US review
October 17, 2019 Share
X
AZ/Daiichi’s possible breast cancer blockbuster gets fast US review
https://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/

Latest News

Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trial

Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a

Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trial

https://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/

Roche sets analysts purring with strong Q3 results

Roche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines

Roche sets analysts purring with strong Q3 results

https://pharmaphorum.com/news/roche-sets-analysts-purring-with-strong-q3-results/

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

https://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/

See all

Views & analysis

The state of personalised medicine in 2019

Things are good, and they’re getting better. When researchers completed mapping the human genome in 2003, it broke

The state of personalised medicine in 2019

https://pharmaphorum.com/views-analysis-oncology/the-state-of-personalised-medicine-in-2019/

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

Transforming oncology with a pan-European approach to data sharing

Between genomic data, electronic health records and digital health tools, we have all the information we need to

Transforming oncology with a pan-European approach to data sharing

https://pharmaphorum.com/views-analysis-oncology/transforming-oncology-with-a-pan-european-approach-to-data-sharing/

See all

Debates & Insights

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

See all

Partner Content

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

RNA Therapeutics Feb 2018

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

https://pharmaphorum.com/partner-content-oncology/this-weeks-spotlight-features-gsk-and-advanced-cell-diagnostics/

See all

Search

Advanced Search

Trending